Search Results

. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients . Ann Surg 1999 ; 230 : 1 – 8 . 30 Dupuy DE Zagoria RJ Akerley W . Percutaneous radiofrequency ablation of malignancies in the lung . AJR

comparison of radio-frequency thermal ablation versus percutaneous ethanol injection . Radiology 2003 ; 228 : 235 – 240 . 36. Livraghi T Bolondi L Lazzaroni S . Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in

Endoscopic Biliary Drainage “From an endoscopy standpoint, knowing the different segments of the liver is crucial in terms of being able to provide biliary decompression,” declared Dr. Kahaleh. “Everything we do is based on symptoms and imaging,” he added

laparoscopic, ultrasound-guided microwave ablation (LMA) for the management of primary and metastatic malignancy to the liver alone or in combination with additional loco-regional therapy (Y-90 radioembolization) and/or systemic chemotherapy or immunotherapy

's esophagus cases to reduce the risk of synchronous or metachronous lesions. Complete remission ranges from 94% to 97% for patients undergoing CBE-EMR for HGD or intramucosal adenocarcinoma, with focal radiofrequency ablation used in some cases. 54 However

use in premenopausal women, there are long-term risks of ovarian ablation (OA), which is a necessary additional intervention in women who still have ovarian function. A recent study found that OA preceeding an AI (OA/AI) was more costly and less

Evidence-based HCC management guidelines have been updated to take full advantage of current treatment options, including transplantation, surgical resection, radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), transarterial

Tamoxifen for Longer Against Shorter (ATLAS) Trial is comparing 5 to 10 years, and the Adjuvant Tamoxifen Treatment Offer More (ATTOM) trial is comparing 5 years with various longer durations. Ovarian Ablation or Suppression in the Premenopausal Setting The

, preferably, endoscopic mucosal resection (EMR) biopsy of the lesion to evaluate for submucosal extension. For patients with a T1aN0M0 tumor, treatment options include EMR with negative pathologic margins and ablation of at-risk adjacent mucosa or

. Fourth, image-guided percutaneous radiofrequency ablation (RFA) and laparoscopically assisted RFA may allow for management of limited metastatic disease and spare patients the toxicity associated with ongoing cytotoxic chemotherapy. Lastly, the